This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
All content for Condensed IP is the property of Randy Noranbrock and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
Hyatt v. Stewart (Fed. Cir., August 29, 2025) 2018-2390, -2391, -2392, 2019-1038, -1039, -1049, -1070, 2024-1992, -1993, -1994, -1995
Condensed IP
10 minutes
2 months ago
Hyatt v. Stewart (Fed. Cir., August 29, 2025) 2018-2390, -2391, -2392, 2019-1038, -1039, -1049, -1070, 2024-1992, -1993, -1994, -1995
This judicial opinion from the United States Court of Appeals for the Federal Circuit details the ongoing litigation in the case of Gilbert P. Hyatt v. Coke Morgan Stewart, focusing on patent applications filed by Hyatt in the 1990s. The court addresses Hyatt's appeals concerning the affirmative defense of prosecution laches asserted by the United States Patent and Trademark Office (PTO), and Hyatt's cross-appeals regarding the district court's lack of Article III jurisdiction over certain cl...
Condensed IP
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
